Phosphodiesterase type 5 (PDE5) inhibitors are the most successful class of oral drugs in sexual medicine, but they are not universally effective. A meaningful minority of men who start sildenafil or tadalafil report an inadequate erectile response despite correct use, and this group — described in the urological literature as PDE5 inhibitor non-responders — represents one of the more difficult problems in outpatient andrology. Understanding why first-line therapy fails, and what the evidence actually supports as a next step, matters more than escalating doses at random. This article reviews the mechanisms behind PDE5 inhibitor non-response and examines the clinical rationale for dual-agent oral therapy, the approach behind the Mach 1 formulation.
What PDE5 Inhibitor Non-Response Actually Means
Non-response is a clinical label, not a biological diagnosis. In practice it describes a man who has taken an adequate dose of a PDE5 inhibitor, on multiple separate occasions, under conditions permitting sexual stimulation, and who has not achieved an erection sufficient for satisfactory intercourse.
That definition carries three qualifiers that are frequently violated in real-world use. The dose must be adequate — many men are never escalated beyond a starting dose. The number of attempts must be sufficient — guidance in the field has long suggested that several trials, not one or two, are needed before declaring failure. And sexual stimulation must be present, because PDE5 inhibitors amplify an existing nitric oxide signal rather than initiating one. A drug that depends entirely on endogenous nitric oxide release cannot work in its absence.
When these conditions are properly met and the response is still inadequate, the failure is genuine and warrants investigation rather than a simple repeat prescription. Cost-effectiveness modelling of what happens after a failed first-line PDE5 inhibitor trial has shown that the choice of second-line pathway has substantial downstream consequences for both outcomes and expenditure, which argues for a deliberate, evidence-guided next step rather than trial-and-error [1].
Why First-Line PDE5 Therapy Fails
The causes of non-response fall into several recognisable groups, and they are not equally common.
Inadequate dosing and incorrect administration. This is the largest single category and the most reversible. Sildenafil absorption is delayed and blunted by a high-fat meal; onset is often misjudged; and a substantial proportion of men are never titrated to the maximum tolerated dose before being labelled treatment-resistant.
Endothelial and metabolic disease. PDE5 inhibitors act downstream of nitric oxide synthase. Where the endothelium is damaged, the upstream signal is weak and there is less cyclic GMP for the drug to preserve. A 2023 analysis of predictors of PDE5 inhibitor treatment failure identified elevated HbA1c as a significant independent factor, alongside low free testosterone and elevated sex hormone-binding globulin [2]. Poorly controlled diabetes is, in this sense, not merely a comorbidity but a direct pharmacological obstacle.
Hypogonadism. Androgens support nitric oxide synthase expression in cavernosal tissue. Low free testosterone was among the failure predictors identified in the same 2023 cohort [2], and it is one of the reasons a hormonal assessment belongs in any non-responder workup.
Severe vascular or neurogenic injury. Advanced atherosclerotic disease, cavernosal fibrosis, and post-surgical nerve injury can limit the substrate on which any oral agent depends.
Psychogenic and relational factors. Performance anxiety and partner-related distress can suppress the central arousal signal regardless of peripheral pharmacology, and they frequently coexist with organic disease rather than replacing it.
What the Evidence Shows About Combination and Dual-Agent Therapy
The question of what to do after monotherapy fails has been examined systematically. A 2019 systematic review in Sexual Medicine Reviews specifically addressed oral combination therapy for erectile dysfunction when PDE5 inhibitor monotherapy fails, and found that chronic treatment with tadalafil, alone or combined with on-demand sildenafil, produced comparable improvements in IIEF-5 scores — establishing that combined PDE5 strategies are a studied rather than improvised approach [3].
A broader 2021 systematic review and meta-analysis published in JAMA Network Open assessed combination therapies against monotherapy across the treatment landscape. It found that adding a second modality — including daily tadalafil alongside other first-line treatments — produced beneficial outcomes relative to single-agent therapy in appropriately selected patients [4]. The signal is consistent: for men whose response to one agent is partial, adding a second mechanism or a second pharmacokinetic profile tends to outperform simply continuing the first.
More recently, a 2025 analysis in Cureus examined predictors of dual PDE5 inhibitor therapy specifically in men with erectile dysfunction and diabetes — a population in which monotherapy non-response is disproportionately common — and noted the absence of adequate data for non-responders as the motivation for the study [5]. This remains an area where clinical practice has moved somewhat ahead of large randomised evidence, and that should be stated plainly rather than overclaimed.
It is also worth noting what the evidence does not support. A 2024 network meta-analysis of nutraceutical interventions for erectile dysfunction in the Journal of Sexual Medicine found the efficacy of supplement-based approaches to be doubtful and the comparative data thin [6]. Men who have failed a PDE5 inhibitor are a frequent target for over-the-counter alternatives; the evidence base for those alternatives is considerably weaker than for prescription pharmacotherapy.
Inside Mach 1: The Pharmacology of Sildenafil 70 mg Plus Tadalafil 20 mg
Mach 1 combines sildenafil 70 mg with tadalafil 20 mg in a single prescription formulation. The rationale is pharmacokinetic rather than novel-mechanism: both molecules inhibit PDE5, but they do so with different absorption curves, half-lives, and receptor selectivity profiles.
Sildenafil reaches peak plasma concentration rapidly and has a short elimination half-life, which produces a steep, early onset of effect. Tadalafil absorbs more slowly and has a markedly longer half-life, which produces a lower but far more sustained plasma concentration. Delivered together, the two create a composite exposure curve that neither achieves alone: an early peak carried forward by a long tail.
For a man whose non-response reflects a narrow or mistimed therapeutic window — the most common practical failure mode after under-dosing — that composite profile addresses the problem directly. It reduces dependence on precise timing relative to intercourse, which is itself a documented source of apparent treatment failure.
The dosing is deliberately at the higher end of the range for both agents, which is why Mach 1 is positioned as a maximum-strength option rather than a starting point. It is intended for men who have already established that standard-dose monotherapy is insufficient, not for men beginning treatment. Clinical studies suggest that combined PDE5 approaches may support better outcomes in this group [3][4], and some men experience a meaningful response where single-agent therapy did not deliver one.
Candidacy, Safety, and How It Is Taken
Mach 1 is a prescription product and requires physician evaluation. That requirement is substantive, not procedural.
The most important contraindication is concurrent nitrate therapy. Organic nitrates and PDE5 inhibitors act on the same nitric oxide–cyclic GMP pathway, and their combination can produce profound hypotension; a 2018 review in the Journal of Cardiovascular Pharmacology and Therapeutics re-examined this interaction in detail and its clinical management [7]. Men taking nitrates for angina, or who may require them acutely, should not take any PDE5 inhibitor. Alpha-blockers, certain antihypertensives, and CYP3A4 inhibitors also require dose review.
Beyond drug interactions, appropriate candidacy involves confirming that the non-response is genuine. A reasonable workup includes verifying that previous trials used adequate doses across multiple attempts, checking fasting glucose or HbA1c, measuring morning total and free testosterone, and reviewing cardiovascular risk — since erectile dysfunction frequently precedes symptomatic coronary disease. Escalating to a high-dose dual-agent formulation without that assessment risks treating a symptom while missing its cause.
Side effects follow the known class profile and may be more pronounced at higher combined exposure: headache, flushing, nasal congestion, dyspepsia, and back or muscle ache, the last being more characteristic of tadalafil. These are generally dose-related and transient. Prolonged erection lasting more than four hours is a medical emergency requiring immediate care. Mach 1 is an on-demand product and is not intended for daily use; men seeking a daily regimen should discuss alternatives with their physician. Further discussion of the class and its alternatives is available across the OnyxMD blog.
Conclusion
PDE5 inhibitor non-response is common enough to be a routine clinical problem and specific enough to be worth investigating properly. In a large share of cases the failure is not pharmacological resistance at all but inadequate dosing, poor timing, uncontrolled metabolic disease, or untreated hypogonadism — all of which are addressable. Where the failure is genuine, the published evidence supports combined and dual-agent oral strategies over indefinite repetition of a monotherapy that has already proven insufficient, while the evidence for over-the-counter alternatives remains weak. The correct sequence is assessment first, then a deliberate escalation, under medical supervision.
If you're exploring clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at questionnaire.getonyxmd.com. You can read more about the Mach 1 formulation and its clinical rationale.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice.
References
Moses RA, Anderson RE, Kim J, Keihani S, Craig JR, Myers JB, Lenherr SM, Brant WO, Hotaling JM. Erectile dysfunction management after failed phosphodiesterase-5-inhibitor trial: a cost-effectiveness analysis. Translational Andrology and Urology. 2019;8(4):387-394. doi:10.21037/tau.2019.03.10
Albarakati M, El-Tholoth HS, Alzahrani A, Alghamdi OS, Alquliti A, Alnuami M, Althobity A, Almardawi A, Bedaiwi K. Predictors of phosphodiesterase type 5 inhibitor treatment failure in patients diagnosed with erectile dysfunction. Cureus. 2023;15(12):e50515. doi:10.7759/cureus.50515
Munk NE, Knudsen JS, Comerma-Steffensen S, Simonsen U. Systematic review of oral combination therapy for erectile dysfunction when phosphodiesterase type 5 inhibitor monotherapy fails. Sexual Medicine Reviews. 2019;7(3):430-441. doi:10.1016/j.sxmr.2018.11.007
Mykoniatis I, Pyrgidis N, Sokolakis I, Ouranidis A, Sountoulides P, Haidich AB, van Renterghem K, Hatzichristodoulou G, Hatzichristou D. Assessment of combination therapies vs monotherapy for erectile dysfunction: a systematic review and meta-analysis. JAMA Network Open. 2021;4(2):e2036337. doi:10.1001/jamanetworkopen.2020.36337
Pande A, Jha A, Chandra K, Pathak A, Kalra S. Predictors of dual phosphodiesterase type 5 inhibitor therapy in persons with erectile dysfunction and diabetes. Cureus. 2025;17(9):e91566. doi:10.7759/cureus.91566
Barbonetti A, Tienforti D, Antolini F, Spagnolo L, Cavallo F, Di Pasquale AB, Maggi M, Corona G. Nutraceutical interventions for erectile dysfunction: a systematic review and network meta-analysis. Journal of Sexual Medicine. 2024;21(11):1054-1063. doi:10.1093/jsxmed/qdae123
Kloner RA, Goggin P, Goldstein I, Hackett G, Kirby MG, Osterloh I, Parker JD, Sadovsky R. A new perspective on the nitrate–phosphodiesterase type 5 inhibitor interaction. Journal of Cardiovascular Pharmacology and Therapeutics. 2018;23(5):375-386. doi:10.1177/1074248418771896
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.